Approaches for targeting cancer stem cells drug resistance

被引:27
作者
Rosa, Roberta [1 ]
D'Amato, Valentina [1 ]
De Placido, Sabino [1 ]
Bianco, Roberto [1 ]
机构
[1] Univ Napoli Federico II, Dipartimento Med Clin & Chirurg, Via Pansini 5, I-80131 Naples, Italy
关键词
Cancer stem cells; resistance; stemness; EMT; immune evasion; EPITHELIAL-MESENCHYMAL TRANSITION; FOCAL ADHESION KINASE; PROSTATE-CANCER; OVARIAN-CANCER; LUNG-CANCER; PHASE-II; PI3K/AKT/MTOR PATHWAY; DOCETAXEL RESISTANCE; MYELOID-LEUKEMIA; IMMUNE-RESPONSES;
D O I
10.1080/17460441.2016.1243525
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Several reports have suggested that a population of undifferentiated cells known as cancer stem cells (CSCs), is responsible for cancer formation and maintenance. In the last decade, the presence of CSCs in solid cancers have been reported. Areas covered: This review summarizes the main approaches for targeting CSCs drug resistance. It is indeed known that CSCs may contribute to resistance to conventional chemotherapy, radiotherapy and targeted agents. Among the mechanisms by which CSCs escape anticancer therapies, removal of therapeutic agents by drug efflux pumps, enhanced DNA damage repair, activation of mitogenic/anti-apoptotic pathways; the main features of CSCs, stemness and EMT, are involved, as well as the capability to evade immune response. Expert opinion: Different approaches are suitable to target CSCs mediated drug resistance. Some of them are currently under clinical evaluation in different cancer types. A better understanding of CSC biology, as well as more accurate study design, may maximize the therapeutic effects of these agents. In this respect, it is important to establish: (i) which molecules should be targeted; (ii) what drug combinations may be suitable; (iii) which patient settings will CSC targeting offer the highest clinical benefit; and (iv) how to integrate therapeutic approaches targeting CSCs with standard cancer therapy.
引用
收藏
页码:1201 / 1212
页数:12
相关论文
共 118 条
[91]   Normal stem cells and cancer stem cells: similar and different [J].
Shackleton, Mark .
SEMINARS IN CANCER BIOLOGY, 2010, 20 (02) :85-92
[92]   Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship [J].
Shapiro, Irina M. ;
Kolev, Vihren N. ;
Vidal, Christian M. ;
Kadariya, Yuwaraj ;
Ring, Jennifer E. ;
Wright, Quentin ;
Weaver, David T. ;
Menges, Craig ;
Padval, Mahesh ;
McClatchey, Andrea I. ;
Xu, Qunli ;
Testa, Joseph R. ;
Pachter, Jonathan A. .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (237)
[93]   Clusterin Mediates TGF-β-Induced Epithelial-Mesenchymal Transition and Metastasis via Twist1 in Prostate Cancer Cells [J].
Shiota, Masaki ;
Zardan, Anousheh ;
Takeuchi, Ario ;
Kumano, Masafumi ;
Beraldi, Eliana ;
Naito, Seiji ;
Zoubeidi, Amina ;
Gleave, Martin E. .
CANCER RESEARCH, 2012, 72 (20) :5261-5272
[94]   Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms [J].
Singh, Brahma N. ;
Fu, Junsheng ;
Srivastava, Rakesh K. ;
Shankar, Sharmila .
PLOS ONE, 2011, 6 (11)
[95]   A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors [J].
Smith, David C. ;
Eisenberg, Peter D. ;
Manikhas, Georgy ;
Chugh, Rashmi ;
Gubens, Matthew A. ;
Stagg, Robert J. ;
Kapoun, Ann M. ;
Xu, Lu ;
Dupont, Jakob ;
Sikic, Branimir .
CLINICAL CANCER RESEARCH, 2014, 20 (24) :6295-6303
[96]   Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function [J].
Storm, Elaine E. ;
Durinck, Steffen ;
de Sousa e Melo, Felipe ;
Tremayne, Jarrod ;
Kljavin, Noelyn ;
Tan, Christine ;
Ye, Xiaofen ;
Chiu, Cecilia ;
Thinh Pham ;
Hongo, Jo-Anne ;
Bainbridge, Travis ;
Firestein, Ron ;
Blackwood, Elizabeth ;
Metcalfe, Ciara ;
Stawiski, Eric W. ;
Yauch, Robert L. ;
Wu, Yan ;
de Sauvage, Frederic J. .
NATURE, 2016, 529 (7584) :97-+
[97]   Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine [J].
Taipale, J ;
Chen, JK ;
Cooper, MK ;
Wang, BL ;
Mann, RK ;
Milenkovic, L ;
Scott, MP ;
Beachy, PA .
NATURE, 2000, 406 (6799) :1005-1009
[98]   Hedgehog beyond medulloblastoma and basal cell carcinoma [J].
Teglund, Stephan ;
Toftgard, Rune .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2010, 1805 (02) :181-208
[99]   PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting [J].
Thorpe, Lauren M. ;
Yuzugullu, Haluk ;
Zhao, Jean J. .
NATURE REVIEWS CANCER, 2015, 15 (01) :7-24
[100]   Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab [J].
Topalian, Suzanne L. ;
Sznol, Mario ;
McDermott, David F. ;
Kluger, Harriet M. ;
Carvajal, Richard D. ;
Sharfman, William H. ;
Brahmer, Julie R. ;
Lawrence, Donald P. ;
Atkins, Michael B. ;
Powderly, John D. ;
Leming, Philip D. ;
Lipson, Evan J. ;
Puzanov, Igor ;
Smith, David C. ;
Taube, Janis M. ;
Wigginton, Jon M. ;
Kollia, Georgia D. ;
Gupta, Ashok ;
Pardoll, Drew M. ;
Sosman, Jeffrey A. ;
Hodi, F. Stephen .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) :1020-+